Egrifta (Tesamorelin) Compounded Equivalent: Cost, Access, and What Women Need to Know

Import from '@/components/mdx'

What Is Tesamorelin and Why Are Women Asking About It?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile growth hormone (GH) secretion, which in turn raises insulin-like growth factor 1 (IGF-1) and promotes visceral fat reduction. The FDA approved the brand-name product Egrifta SV in 2010 specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.

Women are asking about tesamorelin for reasons that extend well beyond that narrow indication.

• Visceral fat gain in perimenopause and post-menopause is driven partly by declining GH pulsatility, a sex-specific phenomenon that accelerates after the final menstrual period.
• Women with polycystic ovary syndrome (PCOS) show blunted GH secretion and elevated IGF-1 resistance patterns that differ from those seen in men with metabolic syndrome.
• Compounded peptide prescribing has grown sharply since 2022, and tesamorelin appears frequently alongside other GHRH/secretagogue compounds in women's metabolic health conversations.

Because the approved indication is narrow, most women seeking tesamorelin are paying entirely out of pocket, which is exactly why the brand-versus-compounded price gap matters so much.

The Real Cost Gap: Brand Egrifta vs. Compounded Tesamorelin

Brand-Name Egrifta SV Pricing

Egrifta SV (the reformulated single-vial version, 2 mg) carries a cash price of approximately $3,500 per month at major pharmacy chains as of early 2026. This figure reflects the wholesale acquisition cost plus typical retail markup; actual pharmacy prices vary by region and can be higher.

Theratechnologies has offered a patient assistance program for qualifying patients, though eligibility criteria change frequently. Women should call the manufacturer directly at 1-833-EGRIFTA to verify current program terms before assuming any discount applies.

Compounded Tesamorelin: The 503A and 503B Distinction

Compounded tesamorelin is available from two classes of pharmacy:

503A pharmacies compound for individual patients under a valid prescription. Quality oversight is primarily state-based. These pharmacies can legally compound tesamorelin because it appears on FDA bulk drug substance lists that have been subject to ongoing regulatory review.

503B outsourcing facilities produce larger batches, undergo FDA inspection on a registration basis, and must meet current Good Manufacturing Practice (cGMP) standards similar to drug manufacturers. Products from 503B facilities carry somewhat more standardized quality assurance.

Average compounded tesamorelin pricing runs approximately $350 per month, though you will see ranges from $200 to $500 depending on dose, diluent included, and pharmacy overhead. A typical starting protocol uses 1 mg subcutaneously once daily at bedtime, with some providers titrating to 2 mg.

The 90 percent price difference is real but comes with trade-offs: compounded products are not FDA-approved, batch-to-batch potency can vary if the pharmacy lacks cGMP infrastructure, and sterility standards depend entirely on the individual facility's practices. Ask any compounding pharmacy for a current Certificate of Analysis before you fill a prescription.

Why the Price Gap Exists

Theratechnologies holds patent and orphan drug exclusivity on the tesamorelin molecule's specific HIV-lipodystrophy formulation. Because tesamorelin is not a small-molecule drug with a traditional generic pathway, there is no FDA-approved generic equivalent. Compounding operates under a separate legal framework (Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act) that permits pharmacies to prepare copies of approved drugs when certain conditions are met. The FDA's oversight of GHRH-analogue peptides in compounding has been evolving since 2023; check the FDA's current bulk drug substance list before initiating therapy, because legal availability can shift within months.

Insurance Coverage for Egrifta: What Women Actually Encounter

When Insurance Pays

Most commercial insurers and Medicare Part D plans cover Egrifta only for its FDA-approved indication: reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. You will need:

1. A documented HIV diagnosis and antiretroviral treatment record.
2. Imaging or clinical confirmation of lipodystrophy (often a DEXA scan or CT).
3. Prior authorization, which typically requires the prescriber to attest that diet and exercise have been tried.

Medicaid coverage varies sharply by state. Some state Medicaid programs cover Egrifta for HIV patients; many do not. Prior authorization requirements differ by plan year.

When Insurance Does Not Pay (Most Women's Situation)

Women seeking tesamorelin for off-label purposes, including visceral adiposity related to menopause, metabolic syndrome, PCOS, or adult growth hormone deficiency not caused by HIV, will almost universally face denial. Off-label prescribing is legal for clinicians but insurers are not obligated to cover it.

A Letter of Medical Necessity from your provider rarely changes the outcome for tesamorelin specifically, though it is worth submitting for the appeals record.

The Manufacturer Coupon and Savings Programs

Theratechnologies has historically offered a Theratechnologies Patient Support Program that can reduce out-of-pocket costs for commercially insured patients who meet eligibility criteria. As of early 2026:

• The program is primarily structured for patients with an HIV-lipodystrophy diagnosis who have commercial insurance.
• Uninsured women paying cash are directed toward a separate access program, but availability is limited and income-based.
• Coupon card programs (pharmacy benefit-linked cards, sometimes marketed through copay assistance platforms) have been available intermittently.

Verify all program terms directly with Theratechnologies before assuming any savings apply. Programs change without notice, and third-party coupon aggregator sites frequently display outdated information.

Sex-Specific Physiology: How Tesamorelin Works Differently in Women

This section matters. Most tesamorelin clinical trials enrolled predominantly male HIV-positive patients, so direct evidence in women is thin. What follows separates what is studied from what is extrapolated.

Growth Hormone Pulsatility Across the Female Life Cycle

Women have naturally higher GH pulse amplitude than men during reproductive years, an effect driven by estrogen stimulation of GH secretion at the pituitary. Estrogen increases GH pulse amplitude and reduces hepatic IGF-1 sensitivity, which means baseline IGF-1 levels in premenopausal women tend to run lower than in age-matched men despite similar or higher GH output. This has a direct dosing implication: a 1 mg/day tesamorelin dose may produce different IGF-1 increments in a 35-year-old cycling woman versus a 58-year-old post-menopausal woman on no hormone therapy.

After menopause, GH pulsatility declines significantly alongside estrogen loss. Visceral fat accumulation accelerates in a pattern distinct from premenopausal women and from men. Whether this menopause-specific GH decline responds to tesamorelin the same way HIV-lipodystrophy does has not been studied in a randomized trial. This is an extrapolation, not established fact.

The Menstrual Cycle and IGF-1 Testing

If you are premenopausal and your provider is monitoring IGF-1 levels on tesamorelin, the timing of the draw matters. IGF-1 concentrations fluctuate modestly across the menstrual cycle, rising slightly in the follicular phase. Standardizing IGF-1 measurements to early follicular phase (days 2 to 5) reduces intra-individual variability and gives a cleaner read on drug effect. Ask your provider to document cycle day at each draw.

PCOS and Tesamorelin

Women with PCOS often show altered GH secretion: blunted GH pulse frequency with compensatory IGF-1 dysregulation tied to insulin resistance. A 2019 review in Fertility and Sterility noted that GH axis dysregulation in PCOS is secondary to hyperinsulinemia rather than primary pituitary dysfunction. Tesamorelin stimulates GH secretion at the pituitary, but if the downstream problem is IGF-1 resistance driven by insulin excess, GH-axis stimulation alone is unlikely to correct visceral fat without concurrent insulin sensitization. No trial has examined tesamorelin specifically in women with PCOS.

Perimenopause and Post-Menopause

The menopause transition is associated with a shift toward central adiposity that mirrors, in some respects, the body composition changes seen in adult GH deficiency. The SWAN study documented a 49 percent increase in visceral adipose tissue over the menopause transition in a multi-ethnic cohort. Whether GHRH analogue therapy could attenuate this shift has not been evaluated in a dedicated menopausal trial. Women asking their providers about tesamorelin for menopause-related visceral fat should understand they are operating in data-extrapolation territory.

A practical framework for providers and women to discuss together:

| Life Stage | GH Axis Status | Tesamorelin Evidence | Clinical Inference | |---|---|---|---| | Reproductive years (cycling) | Higher pulse amplitude; lower IGF-1 | No direct trials | Extrapolated from mixed-sex HIV data | | PCOS | Blunted GH frequency; IGF-1 resistance | No trials | IGF-1 may not normalize without IR treatment | | Perimenopause | Declining GH pulsatility; rising visceral fat | No trials | Mechanistically plausible; unproven | | Post-menopause (no HRT) | Low estrogen; low GH; high visceral fat | No trials | Highest physiological rationale; zero RCT evidence | | Post-menopause (on estrogen HRT) | Estrogen partially restores GH pulsatility | No trials | Estrogen-HRT already improves GH profile; additive benefit unclear |

Pregnancy, Lactation, and Contraception: Read This First

Tesamorelin is contraindicated in pregnancy. This is not a precautionary soft warning. Here is what the data show:

Pregnancy

The Egrifta SV prescribing information classifies tesamorelin as causing fetal harm based on animal reproduction studies. In rat studies, tesamorelin caused fetal toxicity at doses producing exposures below those used clinically in humans. There are no adequate well-controlled studies in pregnant women. IGF-1 elevation during pregnancy carries theoretical risks to fetal growth regulation, as IGF-1 is a key mediator of fetal and placental growth.

If you are trying to conceive, you must stop tesamorelin before attempting pregnancy. There is no established safe washout period defined in the label, but given the peptide's short plasma half-life (approximately 26 minutes for tesamorelin itself, with IGF-1 effects resolving over days to weeks), most providers recommend stopping at least one full menstrual cycle before conception attempts.

Women of reproductive potential should use reliable contraception throughout tesamorelin therapy. This includes women in perimenopause who may still be ovulating irregularly.

Lactation

It is unknown whether tesamorelin or its metabolites transfer into human breast milk. IGF-1 is present in human milk naturally, but whether pharmacologically elevated IGF-1 from tesamorelin would meaningfully increase infant exposure is not established. The prescribing information advises against use during breastfeeding. If you are postpartum and breastfeeding, tesamorelin should be deferred until after weaning.

Contraception Requirements Summary

• Avoid tesamorelin if pregnant or planning pregnancy in the near term.
• Use effective contraception throughout therapy (hormonal contraception, IUD, or barrier methods).
• Perimenopausal women: do not assume irregular cycles mean infertility. Contraception remains necessary until 12 consecutive months without a period (the standard clinical definition of menopause).
• Stop tesamorelin and contact your provider immediately if you have a positive pregnancy test during therapy.

Who This Is Right For, and Who Should Look Elsewhere

Women Who May Be Reasonable Candidates (Off-Label Context)

• Post-menopausal women with documented visceral adiposity who have not responded adequately to diet, exercise, and where indicated, GLP-1 receptor agonist therapy, and who have had IGF-1 levels checked at baseline.
• Women with a documented diagnosis of adult growth hormone deficiency confirmed by stimulation testing, where tesamorelin is being considered as a pituitary-stimulating alternative to recombinant GH injections.
• Women with HIV-associated lipodystrophy: this is the only FDA-approved use, and insurance is most likely to cover it here.

Women Who Should Not Use Tesamorelin

• Anyone pregnant, breastfeeding, or actively trying to conceive.
• Women with active malignancy. Tesamorelin raises IGF-1, and IGF-1 promotes cellular proliferation. The prescribing information explicitly contraindicates use in patients with active malignancy.
• Women with pituitary tumor or structural hypothalamic disease (tesamorelin acts at the pituitary; abnormal pituitary architecture alters response and risk).
• Women with hypersensitivity to tesamorelin or mannitol (present in the formulation).
• Women with diabetic retinopathy: GH elevation can worsen retinopathy. The prescribing information includes a specific warning for this population.

The PCOS Caveat

Women with PCOS face a particular complexity. Insulin resistance, which drives much of PCOS-related visceral fat, is unlikely to be corrected by GH axis stimulation alone. If your provider is considering tesamorelin alongside metformin or a GLP-1 receptor agonist for PCOS-related adiposity, ask for baseline and follow-up IGF-1 monitoring and a clear definition of what a successful treatment response looks like before committing to the cost.

How the Clinical Evidence Stacks Up

The key Phase 3 data for tesamorelin come from two randomized, double-blind, placebo-controlled trials in HIV-positive adults with lipodystrophy. LIPO-010 and LIPO-011 enrolled 816 participants (predominately male) and showed that 2 mg/day tesamorelin reduced visceral adipose tissue by approximately 18 percent versus placebo at 26 weeks as measured by CT scan. Trunk fat on DEXA decreased by about 4 percent. These are the numbers behind every claim you will see about tesamorelin and visceral fat reduction.

Women represented a minority of enrolled participants across these trials. The FDA medical review noted that sex was not a significant effect modifier for the primary visceral fat endpoint, but subgroup analyses in women were not powered to detect sex-specific differences in magnitude of effect or adverse event profile. The honest read: we know tesamorelin reduces visceral fat in HIV-positive adults, most of them men, and we are extrapolating to women.

A 2016 analysis in The Journal of Clinical Endocrinology and Metabolism examined longer-term tesamorelin use (52 weeks) and found that visceral fat reduction was maintained with continued therapy but was largely reversed within 12 weeks of stopping. This is clinically significant for women doing cost-benefit calculations at $350/month: the effect is not durable after discontinuation.

Monitoring While on Tesamorelin

Your provider should check the following at baseline and at regular intervals:

• IGF-1 level: drawn at baseline, at 4 to 6 weeks, and then every 3 to 6 months. Target is the upper half of the age-normalized reference range. The prescribing information recommends dose reduction or discontinuation if IGF-1 exceeds the upper limit of normal.
• Fasting glucose and HbA1c: GH elevation causes transient insulin resistance. Women with prediabetes or PCOS-related insulin resistance need closer glucose monitoring. The LIPO trials showed a small but statistically significant increase in fasting glucose in the tesamorelin arm.
• Visceral fat response: ideally a CT or DEXA at baseline and at 6 months. If there is no measurable reduction by 6 months, the prescribing information recommends discontinuing therapy.
• Injection site reactions: fluid retention, arthralgias, and carpal tunnel symptoms occur in roughly 5 to 8 percent of users. In women, fluid retention may be more noticeable in the luteal phase of the cycle.

Practical Steps to Access Compounded Tesamorelin

1. Get a qualifying prescription. Tesamorelin requires a prescription from a licensed provider. Telehealth providers who specialize in metabolic medicine or anti-aging endocrinology are the most common prescribers for off-label use. Confirm the provider will document a clinical rationale (IGF-1 deficiency, body composition data) to support the prescription.

2. Choose a pharmacy with cGMP documentation. Ask for the pharmacy's most recent FDA 503B registration status or, for 503A pharmacies, state board inspection records. Request a Certificate of Analysis for the specific batch you receive.

3. Verify current legal status. The FDA's position on compounded tesamorelin has been subject to ongoing review under the bulk drug substance nomination process. Check this list before starting, and set a calendar reminder to verify every 6 months that your pharmacy is still in compliance.

4. Understand storage. Lyophilized tesamorelin must be refrigerated before reconstitution and used within a defined window after mixing (typically 24 hours refrigerated). Mishandling degrades potency quickly.

5. Plan injection timing. Standard protocol is subcutaneous injection to the abdomen once daily at bedtime, which aligns with natural nocturnal GH pulsatility. Rotate injection sites to minimize lipohypertrophy.